Hims & Hers stock plunges 19% after Q3 loss and weaker subscriber growth

What happened

Hims & Hers Health reported a third-quarter loss of 14 cents per share and revenue of $890.4 million, up 49% from a year earlier. Its 2.79 million subscribers were 13% higher year over year, but below analyst expectations and down roughly 100,000 from the prior quarter.

Confirmed

Global impact / market context

The results point to a growth trade-off: customers who stayed spent more on average, but the subscriber count fell from the prior quarter and missed forecasts. If reduced advertising continues to limit new sign-ups, slower customer growth could constrain future revenue, even as spending per customer rises.

Analyst inference

The article links the share decline to both a larger-than-expected loss and weaker revenue and subscriber growth. It also notes an earlier 8% share gain after a deal to sell Eli Lilly weight-loss treatments, showing that growth execution and the commercial promise of the deal are both relevant to investor expectations.

Analyst inference

What to watch

1. Watch whether Hims reports subscriber growth returning in later quarters; renewed sign-ups would indicate that the recent decline from the second quarter has eased. Analyst inference
2. Track advertising spending and subscriber additions together, since the article says reduced advertising was the main reason analysts attributed to the sequential subscriber decline. Analyst inference
3. Monitor whether revenue per average subscriber continues rising from $105, which would show if higher customer spending can offset slower growth in the subscriber base. Analyst inference

Evidence

• invezz.com